Kraig Biocraft Laboratories, Inc. IPO Filing Research

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

2026-04-28 · 9999999995-26-001347

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

207,787,193 shares

Class A

2025-11-17 · 0001493152-25-023886

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2025-11-17 · 0001493152-25-023887

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2025-08-18 · 0001493152-25-012131

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

207,787,193 shares

A · Use of proceeds general corporate purposes

2025-08-18 · 0001493152-25-012132

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2025-08-18 · 0001493152-25-012133

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A · Flags dual_class

2025-05-20 · 0001641172-25-011733

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

207,787,193 shares

Class A · Ticker KRAI

2025-05-20 · 0001641172-25-011735

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

306,124,163 shares

Class A · Exchange OTCQB · Ticker KBLB · Includes shares underlying warrants from 2022 and 2021 Yorkville Transactions · Selling stockholders only · Use of proceeds Company receives warrant exercise prices if exercised · Flags warrants

2025-05-06 · 0001641172-25-008855

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

207,787,193 shares · Gross proceeds $10,000,000

Common · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds General corporate purposes · Flags foreign_private_issuer · Underwriters YA II PN, Ltd.

2025-05-06 · 0001641172-25-008856

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2025-04-29 · 9999999995-25-001273

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

2025-04-29 · 9999999995-25-001279

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Common Stock · 2021 Yorkville Warrant to purchase 8,000,000 shares with $0.25 exercise price · Use of proceeds Debt repayment, working capital, and services

2025-02-14 · 0001493152-25-006667

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2025-02-14 · 9999999995-25-000482

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

2025-02-13 · 0001493152-25-006482

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

2025-02-07 · 0001493152-25-005415

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

Class A, Class B · Ticker KBLB

2024-12-09 · 0001493152-24-049282

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A · Exchange OTC · Ticker KRAI

2024-11-19 · 0001493152-24-046805

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2024-08-16 · 0001493152-24-032858

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

306,124,163 shares

Class A · Exchange OTCQB · Ticker KBLB · Includes warrants from 2022 and 2021 Yorkville Transactions and multiple warrant tranches · Selling stockholders only · Use of proceeds No proceeds to the company; proceeds from warrant exercises

2024-06-10 · 0001493152-24-023345

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2024-06-03 · 9999999995-24-001711

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

Class A · Ticker KBLB · Flags dual_class

2023-11-22 · 0001493152-23-042509

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2023-11-16 · 0001493152-23-041677

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

306,124,163 shares

Class A · Exchange OTCQB · Ticker KBLB · Shares include those underlying warrants from various transactions · Selling stockholders only · Use of proceeds Company will receive exercise price of warrants upon exercise

2023-09-11 · 0001493152-23-032263

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2023-09-07 · 9999999995-23-002593

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Ticker KBLB

2023-09-01 · 0001493152-23-031488

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

Ticker KBLB

2023-06-06 · 0001493152-23-020299

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

306,124,163 shares

Class A

2023-05-18 · 0001493152-23-018120

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $5.25 · Range $4.25 to $6.25 · 1,904,762 shares

Class A · Exchange NASDAQ · Ticker KBLB · Over-allotment 285,715 · Each Unit consists of 1 share of Class A Common Stock and 1 warrant to purchase 1 share of Class A Common Stock · Each warrant entitles the holder to purchase 1 share of Class A Common Stock at $5.25 per share · Use of proceeds for general corporate purposes and listing on a national exchange · Underwriters Maxim Group LLC

2023-05-09 · 0001493152-23-015952

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $5.25 · Range $4.25 to $6.25 · 1,904,762 shares

Class A · Exchange NASDAQ · Ticker KBLB · Over-allotment 285,715 · Each Unit consists of one share of Class A Common Stock and one warrant to purchase one share of Class A Common Stock · Each warrant entitles the holder to purchase one share of Class A Common Stock at an exercise price of $5.25 per share · Use of proceeds General corporate purposes · Flags units, warrants · Underwriters Maxim Group LLC

2023-04-27 · 0001493152-23-013831

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

2023-04-14 · 0001493152-23-012378

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

Class A, Class B · The offering includes stock warrants and options, but specific terms are not detailed. · Use of proceeds Proceeds will be used for general corporate purposes, but specifics are not detailed. · Flags dual_class

2022-12-01 · 0001493152-22-034178

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2022-11-17 · 0001493152-22-032746

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

306,124,163 shares

Class A

2022-08-12 · 0001493152-22-022380

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 424B3 filing.

2022-05-25 · 0001493152-22-015052

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

306,124,163 shares

Class A

2022-05-10 · 0001493152-22-012702

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

306,124,163 shares

Class A · Exchange OTCQB · Ticker KBLB · Warrants to purchase common stock issued under the 2022 and 2021 Yorkville Transactions · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, will be used for general corporate purposes

2022-04-19 · 0001493152-22-010459

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior EFFECT filing.

Ticker KBLB

2022-04-14 · 0001493152-22-009930

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

2022-04-08 · 9999999995-22-000890

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Ticker P2Y

2022-03-23 · 0001493152-22-007549

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

2022-02-10 · 0001493152-22-003773

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Kraig Biocraft Laboratories, Inc. filed an S-1/A registration statement for a potential IPO, with the latest amendment dated December 3, 2021. The filing includes financial data and disclosures related to equity structures, convertible debt, and lease agreements, but no explicit details on the offering size, use of proceeds, or business operations are visible in the provided text.

2021-12-03 · 0001493152-21-030443

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Kraig Biocraft Laboratories, Inc. is conducting an IPO offering of 1,904,762 units, each consisting of one share of Class A common stock and one warrant to purchase additional shares. The offering price range is anticipated between $4.25 and $6.25 per unit, with Maxim Group, LLC acting as underwriter. The company aims to list its securities on the Nasdaq Capital Market, though no guarantee of success is provided. The filing includes details on registration fees, stock splits, and risk factors related to market volatility and liquidity.

2021-08-25 · 0001493152-21-021233

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior EFFECT filing.

Price $5.25 · Range $4.25 to $6.25 · 1,904,762 shares

Class A · Exchange Nasdaq · Ticker KBLB · Each Unit consists of 1 share of Class A Common Stock and 1 warrant to purchase 1 share of Class A Common Stock · Warrants to purchase Class A Common Stock at $5.25 per share, exercisable immediately, expiring 5 years from issuance · Use of proceeds for general corporate purposes · Flags units, warrants · Underwriters Maxim Group, LLC

Kraig Biocraft Laboratories, Inc. is conducting a firm commitment underwritten public offering of 1,904,762 units, each consisting of one share of Class A common stock and one warrant to purchase additional shares. The offering price is anticipated between $4.25 and $6.25 per unit, with an option for underwriters to purchase additional shares to cover over-allotments. The company seeks to list its securities on Nasdaq but faces uncertainties regarding market liquidity and listing success. The filing includes updated financial data from its 2020 annual report and 2021 quarterly report.

2021-05-26 · 0001493152-21-012963

424B1 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows S-1/A and confirms the priced prospectus.

207,750,197 shares

Class A · Exchange OTCQB · Ticker KBLB · Warrants issued in connection with convertible notes and separate transactions · Selling stockholders only · Use of proceeds Proceeds from warrant exercises will be received by the company

The current 424B1 filing serves as a prospectus for the resale of 207,750,197 shares of Kraig Biocraft Laboratories, Inc.'s Class A common stock by selling shareholders. These shares include those from secured convertible notes, warrants, and convertible debentures. The company itself is not selling shares or receiving proceeds, though it may receive exercise prices from warrant holders. The filing outlines the resale terms, distribution methods, and risks associated with the offering.

2021-04-21 · 0001493152-21-009376

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B1 and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed an S-1 registration statement for the resale of up to 207,750,197 shares of Class A common stock by selling shareholders. The shares include those from secured convertible notes, warrants, and convertible debentures. The company is not selling shares or receiving proceeds, but may receive warrant exercise prices. The offering terminates upon sale of all shares or compliance with Rule 144. The company's stock is listed on OTCQB, and the filing highlights significant risks, including financial instability and unproven technology.

2021-04-21 · 9999999995-21-001528

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.17 · 207,750,197 shares · Gross proceeds $34,958,783

Class A · Exchange OTCQB · Includes warrants issued in March and December with exercise prices of $0.25 and $0.165 · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders

Kraig Biocraft Laboratories, Inc. filed an amended S-1/A registration statement to correct the stock exchange reference from 'OTCQB' and update the exhibit index to reflect final versions of certain exhibits. The amendment does not alter the substantive content of the registration statement, which relates to the proposed public offering of common stock, warrants, and convertible debentures.

2021-04-15 · 0001493152-21-008888

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.17 · 207,750,197 shares

Class A · Exchange NASDAQ · Warrants issued in March 2021 (exercise price $0.25) and December 2020 (exercise price $0.165) · Selling stockholders only · Use of proceeds Proceeds will go to selling stockholders · Flags warrants

Kraig Biocraft Laboratories, Inc. filed an S-1/A amendment to delay the effectiveness of its registration statement. The amendment is an exhibits-only filing, with no substantive changes to the core offering details. The company remains focused on registering shares underlying convertible debentures and warrants, with no proceeds directly received from selling shareholders. The filing emphasizes the reliance on selling shareholders for share sales and highlights risks associated with the company's financial stability and market liquidity.

2021-04-14 · 0001493152-21-008737

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

Price $0.17 · Range $0.17 to $0.25 · 207,750,197 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB · Warrants issued in March and December 2020, exercisable for Class A Common Stock · Selling stockholders only · Use of proceeds Proceeds from warrant exercises, if any, go to the company; otherwise, proceeds go to selling stockholders

Kraig Biocraft Laboratories, Inc. is a biotechnology company focused on developing high-strength spider silk fibers using genetic engineering for technical textiles. The company is offering 207,750,197 shares of Class A Common Stock through selling shareholders, including shares from secured convertible debentures, warrants, and amended debt instruments. The offering is a resale by shareholders, with the company not receiving proceeds directly. The shares are listed on OTCQB, and the company aims to transition to a national exchange post-offering.

2021-04-05 · 0001493152-21-007987

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $5.25 · Range $4.25 to $6.25 · 1,904,762 shares · Gross proceeds $11,500,000

Class A Common Stock · Exchange OTCQB · Ticker KBLB · Over-allotment 285,714 · Each Unit consists of one share of Class A Common Stock and one warrant to purchase one share of Class A Common Stock · Warrants to purchase one share of Class A Common Stock at $5.25 per share, exercisable 6 months after effectiveness, expiring 5 years from issuance · Use of proceeds General corporate purposes, including working capital and research and development · Flags units, warrants · Underwriters Maxim Group, LLC

Kraig Biocraft Laboratories, Inc. is conducting a firm commitment underwritten public offering of 1,904,762 units at an assumed initial price of $5.25 per unit, with an option for underwriters to purchase additional units. The offering includes Class A common stock and warrants, with proceeds intended for general corporate purposes. The company seeks Nasdaq listing but faces risks related to market uncertainty, lack of established trading markets for warrants, and reliance on underwriters. A reverse stock split is proposed but not reflected in financial statements.

2021-02-18 · 0001493152-21-004268

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $5.25 · Range $4.25 to $6.25 · 1,904,762 shares · Gross proceeds $11,500,000

Class A Common Stock · Exchange Nasdaq · Ticker KBLB · Each Unit consists of one share of Class A Common Stock and one warrant to purchase one share of Class A Common Stock · Warrants to purchase Class A Common Stock at $5.25 per share, exercisable upon 6-month anniversary of effectiveness, expiring 5 years from issuance · Use of proceeds Proceeds will be used for working capital and general corporate purposes · Flags units, warrants · Underwriters Maxim Group, LLC

Kraig Biocraft Laboratories, Inc. filed an S-1/A registration statement for a public offering of 1,904,762 units, each consisting of one share of Class A common stock and one warrant. The offering aims to raise up to $11.5 million, with an option for underwriters to purchase additional units. The company seeks to list its securities on Nasdaq but faces risks related to market volatility, limited trading liquidity, and potential failure to meet listing requirements. The filing includes updates to align with recent financial disclosures and reflects ongoing efforts to comply with regulatory requirements.

2021-02-08 · 0001493152-21-002931

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $5.25 · Range $4.25 to $6.25 · 1,904,762 shares

Class A Common Stock · Exchange Nasdaq · Ticker KBLB · Each Unit consists of one share of Class A Common Stock and one warrant to purchase one share of Class A Common Stock · Warrants exercisable at $5.25 per share (100% of Unit price) with 5-year term · Use of proceeds Proceeds will be used for general corporate purposes, including working capital and potential acquisitions · Underwriters Maxim Group, LLC

Kraig Biocraft Laboratories, Inc. is conducting a public offering of 1,904,762 units, each consisting of one share of Class A common stock and one warrant to purchase additional shares. The offering is underwritten by Maxim Group LLC, with an assumed initial price of $5.25 per unit. The company aims to list its securities on Nasdaq but faces risks related to market volatility, limited operating history, and dependence on a single product. The filing amends prior disclosures to remove a fixed unit price and use a price range instead.

2020-08-24 · 0001493152-20-016636

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Gross proceeds $11,500,000

Class A Common Stock · Exchange Nasdaq · Ticker KBLB · Units consisting of shares of Class A Common Stock and warrants · Warrants to purchase shares of Class A Common Stock at an exercise price of $[●] per share, expiring five years from issuance · Flags units, warrants · Underwriters Maxim Group, LLC

Kraig Biocraft Laboratories, Inc. is conducting an IPO via Form S-1, offering units consisting of Class A Common Stock and warrants. The company, a Wyoming-based biotechnology firm, seeks to raise up to $11.5 million, with underwriters having an option to purchase additional units. The filing highlights the company's controlled structure, with CEO Kim Thompson owning 51.01% of voting power. The offering includes a reverse stock split not reflected in financial statements, and the company aims to list on Nasdaq, though this is not guaranteed. The prospectus emphasizes high investment risks, including lack of established market for warrants and dependence on a single director's control.

2020-06-02 · 0001493152-20-010402

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

110,000,000 shares

Class A · Exchange NASDAQ · Ticker KRAI

The prospectus supplement updates the company's previously filed prospectus with the inclusion of its quarterly report on Form 10-Q for the period ended March 31, 2017. This supplement amends the prospectus to reflect updated financial information and disclosures, emphasizing that the prospectus must be read in conjunction with this supplement.

2017-06-12 · 0001654954-17-005506

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

The filing confirms the effectiveness of Kraig Biocraft Laboratories, Inc.'s securities offering, with the Notice of Effectiveness dated May 8, 2017. The previous 424B3 filing included a Prospectus Supplement No. 2, which incorporated the company's Quarterly Report on Form 10-Q for the period ended September 30, 2016. The current filing signals the company's readiness to proceed with its offering, building on prior disclosures.

2017-05-08 · 9999999995-17-001212

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

110,000,000 shares

Class A

The current filing updates the prospectus for Kraig Biocraft Laboratories, Inc. with the Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. This supplement incorporates updated financial data, including a net loss of $2.16 million for the nine months ended September 30, 2016, compared to $1.73 million for the same period in 2015. The filing emphasizes the high risk of investing in the company's securities and references the risk factors section of the prospectus.

2016-12-07 · 0001654954-16-004659

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

110,000,000 shares

Class A

The current filing updates the prospectus for Kraig Biocraft Laboratories, Inc. with the company's Quarterly Report on Form 10-Q for the period ended June 30, 2016. The supplement incorporates updated financial statements, including condensed balance sheets, statements of operations, stockholders' deficit, and cash flows. The offering remains focused on the resale of up to 110,000,000 shares of Class A common stock under a put right agreement with Calm Seas Capital, LLC, with proceeds intended for working capital and research and development.

2016-10-21 · 0001654954-16-003014

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

110,000,000 shares

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from the resale are not received by the issuer · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering up to 110,000,000 shares of Class A common stock for resale by Calm Seas Capital, LLC under a put right agreement. The company will not receive proceeds from the resale but will access capital via an equity line financing. The offering includes risks related to stock price volatility, reliance on the put right for funding, and financial instability, including an accumulated deficit and a going concern opinion. The shares are traded on OTCQB under 'KBLB.'

2016-07-29 · 0001654954-16-001014

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $0.04 · 110,000,000 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. filed Amendment No. 8 to its Form S-1 registration statement, incorporating disclosures from its 2015 10-K and 2016 10-Q filings. The filing relates to the resale of up to 110 million shares of Class A common stock by Calm Seas Capital, LLC under a 'put right' agreement. The company, in the R&D stage, seeks to fund operations and expand production of genetically engineered silk fibers. It has no revenue, significant accumulated losses, and a going concern opinion from auditors. Proceeds from the equity line financing will cover R&D, operational costs, and legal fees.

2016-06-16 · 0001654954-16-000512

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed a Notice of Effectiveness for its securities registration on June 14, 2016, following an earlier S-1 filing in June 2015. The current filing confirms the effectiveness of the registration statement, indicating the company was cleared to proceed with its securities offering.

2016-06-14 · 9999999995-16-004897

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed a Notice of Effectiveness for its S-1 registration statement, enabling the resale of 110 million shares of Class A common stock by Calm Seas Capital, LLC. The shares are subject to a 'put right' under a letter agreement, allowing the company to sell up to $7.5 million in shares over two years. The company will not receive proceeds from the resale but may access capital through the put mechanism. The filing reflects amendments to exhibits and legal disclosures.

2015-06-05 · 9999999995-15-001539

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.04 · 110,000,000 shares

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds for the company's operations and product development · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A Common Stock for resale by Calm Seas Capital, LLC under a put right agreement. The company will not receive proceeds from the resale but may receive capital through exercise of the put right, which allows monthly sales of up to $200,000 in shares at 80% of the lowest trading price over five days. The shares trade on OTCQB under 'KBLB' with a closing price of $0.04 as of June 2, 2015.

2015-06-02 · 0001354488-15-002814

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.04 · Range $0.04 to $0.04 · 110,000,000 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds No issuer proceeds; all proceeds go to selling stockholders · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A common stock for resale by Calm Seas Capital, LLC under a 'put right' agreement. The company may 'put' up to $7.5 million in shares over two years, with Calm Seas purchasing shares at 80% of the lowest price over five trading days following a put notice. The company will not receive proceeds from the resale but will gain capital upon exercising the put right. The filing includes updates to internal control disclosures, accounting personnel details, and unaudited Q1 2015 financials following SEC comments.

2015-05-15 · 0001354488-15-002541

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

110,000,000 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds selling stockholders with no issuer proceeds · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A common stock for resale by Calm Seas Capital, LLC under a put right agreement. The company will not receive proceeds from the resale but will receive capital through the exercise of the put right, which allows monthly sales of up to $200,000 in shares at 80% of the lowest stock price over five trading days. The offering is structured to provide incremental funding for operations and product development, with a total cap of $7.5 million.

2015-04-03 · 0001354488-15-001589

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.04 · 110,000,000 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds The company will not receive proceeds from the resale; proceeds from the put right will be used for operations and product development. · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A Common Stock for resale by Calm Seas Capital, LLC under a 'put right' agreement. The company will not receive proceeds from the resale but may access up to $7.5 million in capital over two years by 'putting' shares to Calm Seas at 80% of the lowest trading price over five days following a put notice. The offering is structured as an equity line financing with monthly limits and risk factors emphasizing high volatility and lack of revenue.

2015-03-09 · 0001354488-15-001026

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.04 · 110,000,000 shares

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the company will not receive any proceeds · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A Common Stock for resale by Calm Seas Capital, LLC under a 'put right' agreement. The company will not receive proceeds from the resale but may receive capital through exercises of the put right. The shares are traded on OTCQB under 'KBLB' with a recent closing price of $0.0401 as of October 31, 2014. The offering involves significant risks, including market volatility and reliance on the Letter Agreement.

2015-01-30 · 0001354488-15-000385

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.04 · 110,000,000 shares · Gross proceeds $4,411,000

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from the put right will be used for operations and product development · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A common stock for resale by Calm Seas Capital, LLC under a 'put right' agreement. The company will not receive proceeds from the resale but may access capital via the put right, which allows monthly sales of up to $200,000 in shares at 80% of the lowest trading price over five days. The offering is structured to provide flexibility for capital needs, subject to market conditions and regulatory approvals.

2015-01-07 · 0001354488-15-000089

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Price $0.04 · 110,000,000 shares

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, and the company will not receive any proceeds from this offering. · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 110,000,000 shares of Class A Common Stock for resale by Calm Seas Capital, LLC under a new 'put right' agreement. The offering allows the company to sell up to $7.5 million in shares over two years, with monthly puts of $200,000. This replaces previous agreements (2011 and 2013) that had lower limits. The company will not receive proceeds from the resale but may benefit from capital raises via the put mechanism. Shares are traded on OTCQB under 'KBLB' with a recent closing price of $0.0401.

2014-11-03 · 0001354488-14-005376

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

73,853,414 shares

Class A · Exchange OTCQB · Ticker KBLB · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the company will not receive any proceeds. · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. filed a 424B3 prospectus for the resale of 73,853,414 shares of Class A common stock by Calm Seas Capital, LLC, a selling shareholder. The shares are subject to put rights under two letter agreements (2011 and 2013) allowing the company to sell up to $1.475 million in shares under the 2013 agreement. The company does not receive proceeds from the resale but may receive capital through exercised put rights. The stock trades on OTCQB, with a recent closing price of $0.061 per share. High-risk factors include potential loss, stock price volatility, and reliance on capital raises.

2014-05-13 · 0001354488-14-002496

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

The filing confirms the effectiveness of Kraig Biocraft Laboratories, Inc.'s prospectus supplement related to the resale of 73,853,414 shares of Class A Common Stock by Calm Seas Capital, LLC. The supplement incorporates restated financial statements from amended 10-Q/A and 10-K/A filings, addressing previously unaccounted warrants. The company's shares trade on the OTCQB under 'KBLB.PK,' with a closing price of $0.059 as of January 24, 2014.

2014-05-02 · 9999999995-14-001306

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows 424B3 and confirms the priced prospectus.

73,853,414 shares

Class A · Exchange OTCQB · Ticker KBLB.PK · Selling stockholders only · Use of proceeds Proceeds will not be received by the company; selling stockholder will pay selling commissions

The current filing is a prospectus supplement for Kraig Biocraft Laboratories, Inc., amending the June 2013 prospectus to include updated financial information from amended 10-Q and 10-K filings. It details the resale of 73,853,414 shares of Class A common stock by Calm Seas Capital, LLC under put rights from two letter agreements (2011 and 2013). The company does not receive proceeds from the resale but bears registration costs. The filing highlights risks related to financial instability, reliance on a single shareholder, and potential share price volatility.

2014-01-27 · 0001354488-14-000341

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

73,853,414 shares

Class A · Exchange OTCQB · Ticker KBLB.PK · Selling stockholders only · Use of proceeds Proceeds from the put right will be used for operations and product development · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. filed a prospectus (424B3) for the resale of 73,853,414 shares of Class A Common Stock by Calm Seas Capital, LLC. The shares are resold under two 'put rights' agreements (2011 and 2013 Letter Agreements) allowing the company to issue up to $3,435,000 in shares over two years. The company does not receive proceeds from the resale but may receive capital when exercising put rights. The shares trade on the OTCQB under 'KBLB.PK', with a closing price of $0.08 as of June 12, 2013. High-risk factors include stock price volatility and reliance on a single shareholder for capital.

2013-06-26 · 0001354488-13-003614

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed a Notice of Effectiveness for its S-1 registration statement, registering 73,853,414 shares of Class A common stock for resale by selling shareholder Calm Seas Capital, LLC. The registration relates to two letter agreements (2011 and 2013) allowing the company to 'put' shares to Calm Seas under specific pricing terms. The company will not receive proceeds from the resale but may receive capital through exercise of put rights. The filing serves as a post-effective amendment to an earlier registration statement.

2013-06-25 · 9999999995-13-001914

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows 424B3 in the pre-IPO sequence.

Price $0.08 · 73,853,414 shares

A · Exchange OTCQB · Ticker KBLB.PK · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale of shares · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. filed an S-1 registration statement to resell 73,853,414 shares of Class A common stock through Calm Seas Capital, LLC. The shares are subject to two 'put rights' under letter agreements (2011 and 2013) allowing the company to sell up to $935,000 and $2,500,000 in shares, respectively, over two-year periods. The company does not receive proceeds from the resale but may benefit from exercising put rights. This filing updates a prior 424B3 registration, adding new shares and adjusting terms.

2013-06-14 · 0001354488-13-003489

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

63,600,000 shares

Class A · Exchange OTCQB · Ticker KBLB.PK · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the company will not receive any proceeds · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. filed a 424B3 prospectus relating to the resale of up to 63,600,000 shares of Class A common stock by Calm Seas Capital, LLC. The shares are being resold under two 'put rights' agreements (2009 and 2011) allowing the company to sell up to $1,555,000 in shares to Calm Seas at 80% of the lowest closing bid price over five trading days. The company does not receive proceeds from the resale but may receive capital through exercise of the put rights. The stock trades on the OTCQB under 'KBLB.PK' with a closing price of $0.069 as of April 27, 2012.

2012-05-04 · 0001354488-12-002154

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed a Notice of Effectiveness for its registration statement related to the resale of up to 63,600,000 shares of Class A Common Stock by Calm Seas Capital, LLC. The shares are being resold under two 'put right' agreements allowing the company to sell up to $1,955,000 in additional shares. The filing confirms the registration is effective, enabling the resale, but the company will not receive proceeds from the resale, only from exercising put rights under the agreements.

2012-05-03 · 9999999995-12-001404

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

63,600,000 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB.PK · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the company will not receive any proceeds. · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 63,600,000 shares of Class A Common Stock for resale by Calm Seas Capital, LLC under two put agreements. The company will not receive proceeds from the resale but may receive capital through exercising put rights. The shares are traded on OTCQB under 'KBLB.PK'. The offering involves significant risks, including reliance on a single shareholder for capital and unproven technology.

2011-08-15 · 0001354488-11-002745

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed a Notice of Effectiveness for its S-1 registration statement on August 12, 2011, confirming the effectiveness of its securities offering. The filing amends prior registration statements, carrying forward 51,775,856 shares of Class A common stock from a previous registration and adding 11,824,144 new shares for resale by a selling securityholder. The company is a small reporting company, and the offering includes estimated expenses for registration, legal, and accounting fees.

2011-08-12 · 9999999995-11-002490

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

63,600,000 shares

Class A · Selling stockholders only · Use of proceeds Selling stockholders will sell shares, with no proceeds to the issuer

Kraig Biocraft Laboratories, Inc. is registering 63,600,000 shares of Class A Common Stock for resale by Calm Seas Capital, LLC, a selling shareholder. The S-1/A amendment updates the registration to include 11,824,144 additional shares not previously registered, building on the prior S-1 filing. The company will not receive proceeds from the resale but may receive capital via put rights under Letter Agreements with Calm Seas. The shares are traded on the OTCQB under 'KBLB.PK,' and the offering involves significant risks, including potential loss and reliance on speculative market conditions.

2011-08-09 · 0001213900-11-004099

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $0.12 · 63,600,000 shares · Gross proceeds $0.00

Class A · Exchange OTCQB · Ticker KBLB.PK · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale of the shares · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. filed an S-1 registration statement to register 63,600,000 shares of Class A common stock for resale by Calm Seas Capital, LLC, a selling shareholder. The shares are offered under two equity line of credit agreements (2009 and 2011 Letter Agreements), allowing the company to 'put' up to $1,955,000 in shares to Calm Seas. The company will not receive proceeds from the resale but may receive funds upon exercising put rights. The stock trades on OTCQB under 'KBLB.PK' with a recent closing price of $0.118 per share. The filing includes risk factors highlighting high investment risk, development-stage operations, and reliance on equity line agreements.

2011-08-01 · 0001213900-11-003972

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows S-1/A and confirms the priced prospectus.

63,600,000 shares

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from the sale will go to the selling stockholder; the company will not receive any proceeds · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is offering up to 63,600,000 shares of Class A common stock through a resale agreement with Calm Seas Capital, LLC, under a 'put right' provision. The company will not receive proceeds from the resale but will benefit from capital raised via the put right, which allows it to sell up to $1,000,000 in shares over 24 months. The offering is tied to a letter agreement with Calm Seas, enabling monthly sales of up to $75,000 in shares at 80% of the lowest closing bid price. The company faces financial challenges, including an accumulated deficit and a going concern opinion, and relies heavily on this capital structure for operations and research.

2010-06-21 · 0001213900-10-002578

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B3 and marks the registration effective.

Kraig Biocraft Laboratories, Inc. filed an S-1 registration statement for the resale of up to 63,600,000 shares of Class A Common Stock under a put right agreement with Calm Seas Capital, LLC. The offering allows the company to raise up to $1,000,000 by selling shares to Calm Seas at 80% of the lowest closing bid price over five trading days following a put notice. The company does not receive proceeds from the resale but will benefit from the equity line of credit. The shares are traded on the OTCBB under 'KBLB'.

2010-06-21 · 9999999995-10-001881

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

63,600,000 shares

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from the sale will go to the selling shareholder · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is offering up to 63.6 million shares of Class A common stock through a 'put right' agreement with Calm Seas Capital, LLC, allowing the company to raise up to $1 million over two years. The proceeds will fund research and development of recombinant spider silk fibers, with no direct proceeds to the company from share sales. The company faces significant risks, including its history of losses, reliance on a single shareholder for capital, and dependence on university collaborations.

2010-06-15 · 0001213900-10-002470

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

63,600,000 shares

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from exercise of put right for operational capital · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is developing high-strength, protein-based fibers using recombinant DNA technology for specialty fiber and technical textile markets. The company seeks to raise $1 million via an equity line of credit with Calm Seas Capital, LLC, allowing monthly 'puts' of up to $75,000 in shares. Proceeds will fund R&D, with a focus on transgenic silkworms for spider silk production. The company has an accumulated deficit of $4.15 million and a going concern opinion from auditors, relying on external capital to advance its research.

2010-06-03 · 0001213900-10-002317

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.02 · 63,600,000 shares

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from the sale of shares will go to the selling shareholder; the company may receive proceeds from future exercises of the put right · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is registering 63.6 million shares of Class A common stock for resale by Calm Seas Capital, LLC under a put right agreement. The company aims to use proceeds from the equity line of credit to fund research and development of recombinant spider silk fibers. The filing highlights ongoing collaborations with universities, financial challenges including a $4.15 million accumulated deficit, and risks related to intellectual property agreements and research timelines.

2010-04-22 · 0001213900-10-001588

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Price $0.02 · 63,600,000 shares

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds to fund operations and product development · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is seeking to register 63.6 million shares of Class A common stock for resale under a put right agreement with Calm Seas Capital, LLC. The company focuses on developing high-strength protein-based fibers using recombinant DNA technology, with a primary goal of commercializing spider silk fibers. The offering is structured as an equity line of credit, allowing the company to 'put' up to $1 million in shares to Calm Seas over two years. The company has not generated revenue, carries an accumulated deficit, and relies heavily on external financing and research collaborations.

2010-01-25 · 0001213900-10-000288

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Price $0.02 · 63,600,000 shares · Gross proceeds $1,049,400

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds Proceeds from the sale will go to the selling shareholder, with no proceeds to the company · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is seeking to register 63,600,000 shares of Class A common stock for resale by Calm Seas Capital, LLC under a put right agreement. The company, in early development stages, has no revenues and an accumulated deficit of $1.59 million. Proceeds from the equity line of credit will fund research and development, with 95% allocated to non-discretionary expenses. The company relies on collaboration agreements, including a pending renewal with the University of Notre Dame, and faces risks related to research delays and liquidity.

2009-12-16 · 0001213900-09-003653

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Price $0.02 · Range $0.02 to $0.02 · 88,500,000 shares · Gross proceeds $0.00

Class A · Exchange OTCBB · Ticker KBLB · Selling stockholders only · Use of proceeds Selling stockholders will receive proceeds from the sale of shares · Underwriters Calm Seas Capital, LLC

Kraig Biocraft Laboratories, Inc. is offering up to 88,500,000 shares of Class A common stock through a resale agreement with Calm Seas Capital, LLC, under a 'put right' mechanism. The company focuses on developing spider silk fibers using genetic engineering but has not generated revenue, with an accumulated deficit of $1.59 million. The offering allows the company to raise up to $1 million over 24 months by selling shares at 80% of the lowest closing bid price over five trading days. The company does not receive proceeds from the resale but may benefit from the put right. The filing highlights risks related to unproven technology, market volatility, and lack of revenue.

2009-10-02 · 0001213900-09-002710

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

First tracked pre-IPO filing for this issuer.

Kraig Biocraft Laboratories, Inc. filed a Form SB-2 registration statement with the SEC, effective October 16, 2007, indicating the commencement of its initial public offering (IPO) process. The notice of effectiveness signifies the company's readiness to offer securities to the public, though limited details about the offering's terms, business operations, or financials are provided in the filing.

2007-10-16 · 9999999995-07-004065

Kraig Biocraft Laboratories, Inc.

Filing Timeline

10 comparable deals

Recent News